Your browser doesn't support javascript.
loading
Japan Trevo Registry: Real-world Registry of Stent Retriever Alone or in Combined Therapy with Aspiration Catheter for Acute Ischemic Stroke in Japan.
Uchida, Kazutaka; Sakai, Nobuyuki; Yamagami, Hiroshi; Uemura, Kohei; Imamura, Hirotoshi; Takeuchi, Masataka; Shirakawa, Manabu; Sakakibara, Fumihiro; Haraguchi, Koichi; Kimura, Naoto; Suzuki, Kentaro; Ayabe, Junichi; Yamamoto, Daisuke; Shindo, Seigo; Kimoto, Atsushi; Morita, Kenichi; Akiyama, Yoshinori; Takezawa, Hidesato; Toyota, Shingo; Tanaka, Kanta; Kasakura, Shigen; Tsukagoshi, Eisuke; Ueda, Toshihiro; Yoshimura, Shinichi.
Afiliación
  • Uchida K; Department of Neurosurgery, Hyogo Medical University.
  • Sakai N; Department of Neurovascular Research, Kobe City Medical Center General Hospital.
  • Yamagami H; Department of Stroke Neurology, National Hospital Organization Osaka National Hospital.
  • Uemura K; Department of Biostatistics and Bioinformatics, Interfaculty Initiative in Information Studies, The University of Tokyo.
  • Imamura H; Department of Neurovascular Research, Kobe City Medical Center General Hospital.
  • Takeuchi M; Department of Neurosurgery, National Cerebral and Cardiovascular Center.
  • Shirakawa M; Department of Neurosurgery, Seishou Hospital.
  • Sakakibara F; Department of Neurosurgery, Hyogo Medical University.
  • Haraguchi K; Department of Neurosurgery, Hyogo Medical University.
  • Kimura N; Department of Neurosurgery, Hakodate Shintoshi Hospital.
  • Suzuki K; Department of Neurosurgery, Iwate Prefectural Central Hospital.
  • Ayabe J; Department of Neurology, Nippon Medical School.
  • Yamamoto D; Department of Neurosurgery, Yokosuka Kyosai Hospital.
  • Shindo S; Department of Neurosurgery, Kitasato University School of Medicine.
  • Kimoto A; Department of Neurology, Japanese Red Cross Kumamoto Hospital.
  • Morita K; Department of Neurosurgery, Tominaga Hospital.
  • Akiyama Y; Department of Cerebrovascular Medicine, Niigata City General Hospital.
  • Takezawa H; Department of Neurosurgery, Tenri Hospital.
  • Toyota S; Department of Neuroendovascular Therapy and Neurology, Saiseikai Shiga Hospital.
  • Tanaka K; Department of Neurosurgery, Kansai Rosai Hospital.
  • Kasakura S; Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center.
  • Tsukagoshi E; Department of Endovascular Neurosurgery, Saitama Medical University International Medical Center.
  • Ueda T; Department of Endovascular Neurosurgery, Saitama Medical University International Medical Center.
  • Yoshimura S; Department of Strokology and Neuroendovascular Treatment, Stroke Center, St. Marianna University Toyoko Hospital.
Neurol Med Chir (Tokyo) ; 63(11): 503-511, 2023 Nov 15.
Article en En | MEDLINE | ID: mdl-37853613
ABSTRACT
Endovascular therapy (EVT) for real-world patients after extended time frames is associated with concerns about its efficacy and safety. We conducted a prospective registry at 77 centers between November 2019 and October 2020. The registry criteria included patients treated with Trevo Retriever alone or in combined therapy with an aspiration catheter. The primary outcome was effective reperfusion (thrombolysis in cerebral infarction grade ≥ 2b), the secondary outcome was a modified Rankin scale 0-2 at 90 days, and the safety outcomes were worsening of neurologic symptoms within 24 h postoperatively, intracranial hemorrhage (ICH) within 24 h after EVT and mortality. We also exlpored the difference between patients whose last known well time (LKWT) to a puncture was less than 6 h (0-6 h) and those whose LKWT was 6 h or more but less than 24 h (6-24 h). Among the 1041 patients registered, 1025 patients were analyzed. The mean age was 76.9 years, and 53.6% of the participants were males. The 6-24 h group was 206/998 (20.6%), the median National Institute of Health Stroke Scale (NIHSS) score at admission was 18, and the median Alberta Stroke Program Early CT score was 8. Combined technique as the first pass was used on 817 (79.7%) patients. The primary outcome was 934 (91.1%). The secondary outcome was 433/1021 (42.4%). Symptomatic ICH, any ICH, and mortality were 10/1019 (1.0%), 311/1019 (30.5%), and 75 (7.3%). In the subanalysis, the 6-24 h group was lower in NIHSS (median;18 vs 16), and the secondary outcome was not significantly different in the <6 h group. Even after treatment time expansion, this result was comparable to other Trevo-based trials and nationwide registries.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Isquemia Encefálica / Accidente Cerebrovascular / Procedimientos Endovasculares / Accidente Cerebrovascular Isquémico Límite: Aged / Female / Humans / Male País/Región como asunto: Asia Idioma: En Revista: Neurol Med Chir (Tokyo) Año: 2023 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Isquemia Encefálica / Accidente Cerebrovascular / Procedimientos Endovasculares / Accidente Cerebrovascular Isquémico Límite: Aged / Female / Humans / Male País/Región como asunto: Asia Idioma: En Revista: Neurol Med Chir (Tokyo) Año: 2023 Tipo del documento: Article